2025-05-17 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the data you provided, presented as a concise report in English with key figures first, followed by analysis.

**Teladoc Health Inc. (TDOC) Analysis**

**1. Performance vs. S&P 500 (VOO)**

*   **TDOC Cumulative Return:** -67.57%
*   **VOO Cumulative Return:** 80.17%
*   **Relative Deviation:** -147.7 (Relative Deviation Range: -159.2 to 454.5, Current Relative Deviation Position: 1.9)
*   **Company Overview:** Teladoc Health Inc. provides virtual healthcare services, connecting patients with doctors remotely.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
| ---------- | ------ | ------ | ------- | ------ | ------ |
| 2015-2017  | 76.0%  | 60.6%  | 52.0%   | -0.0   | 6.1    |
| 2016-2018  | 128.0% | 59.3%  | 112.0%  | -0.0   | 8.7    |
| 2017-2019  | 176.0% | 59.3%  | 149.0%  | 0.3    | 14.7   |
| 2018-2020  | 237.0% | 64.0%  | 212.0%  | 0.1    | 35.1   |
| 2019-2021  | -83.0% | 64.0%  | -136.0%  | 0.1    | 16.1   |
| 2020-2022  | -295.0% | 81.3%  | -300.0% | 0.0    | 4.2    |
| 2021-2023  | -488.0% | 81.3%  | -504.0% | -0.6   | 3.8    |
| 2022-2024  | -111.0% | 81.3%  | -127.0% | -0.8   | 1.6    |
| 2023-2025  | -38.0% | 72.9%  | -69.0%  | -0.8   | 1.3    |

*   **Analysis:** TDOC has significantly underperformed the S&P 500.  The relative deviation shows extreme underperformance.  The relative deviation position of 1.9 indicates that the current underperformance is near the best relative performance TDOC has shown in the analyzed period, though still deeply negative. Alpha is overwhelmingly negative in recent years, indicating significant underperformance relative to its risk. Beta values are unstable. The capitalization has shrunk

**2. Recent Stock Price Movement**

*   **Current Price:** $7.52
*   **Previous Close:** $7.25
*   **Change:** 3.72%
*   **5-Day Moving Average:** 7.416
*   **20-Day Moving Average:** 7.1365
*   **60-Day Moving Average:** 8.0877

*   **Analysis:** The stock has recently experienced a noticeable positive price change. The price is above the 5-day and 20-day moving averages but below the 60-day moving average. This suggests a short-term upward trend but longer-term resistance.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3475 (Low Risk)
*   **RSI:** 57.14 (Neutral)
*   **PPO:** 1.4657 (Positive Momentum)
*   **20-Day Relative Deviation Change:** -1.2 (Short-Term Decrease)
*   **Expected Return:** -4516.5% (Long-Term, vs. S&P 500)

*   **Analysis:** The MRI indicates low market risk. The RSI is neutral.  The PPO signals positive momentum. The negative change in relative deviation suggests a recent short-term decline in relative performance. The large negative expected return indicates a very pessimistic outlook for TDOC compared to the S&P 500 over the long term. The recent price change indicates an acute event that has moved the price upward.

**4. Recent News & Significant Events**

*   **[2025-05-15]:** Major business developments, regulatory changes, or market events.
*   **[2025-05-16]:** Analyst discussions on performance, industry trends, and global economic factors.
*   **[2025-05-17]:** Notable stock volatility.
*   **[2025-05-13]:** Market expert advice to monitor news and announcements.

*   **Analysis:** Recent news suggests potentially significant events are impacting TDOC, leading to volatility and increased scrutiny.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue   |
| ---------- | ----- | --------- |
| 2025-05-01 | -0.53 | 0.63 B$   |
| 2024-10-31 | -0.19 | 0.64 B$   |
| 2024-08-01 | -4.92 | 0.64 B$   |
| 2024-04-26 | -0.49 | 0.65 B$   |
| 2025-05-01 | -0.49 | 0.65 B$   |

*   **Analysis:** TDOC has consistently reported negative EPS.  Revenue has remained relatively stable, although there appears to be some cyclicality or inaccuracy in the data given the duplicate entry for 2025-05-01.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue | Profit Margin |
| ---------- | ------- | ------------- |
| 2025-03-31 | $0.63B  | 68.73%        |
| 2024-12-31 | $0.64B  | 70.50%        |
| 2024-09-30 | $0.64B  | 71.94%        |
| 2024-06-30 | $0.64B  | 70.73%        |
| 2024-03-31 | $0.65B  | 69.89%        |

Capital and Profitability:

| Quarter    | Equity  | ROE      |
| ---------- | ------- | -------- |
| 2025-03-31 | $1.43B  | -6.52%   |
| 2024-12-31 | $1.49B  | -3.25%   |
| 2024-09-30 | $1.51B  | -2.21%   |
| 2024-06-30 | $1.50B  | -55.77%  |
| 2024-03-31 | $2.29B  | -3.58%   |

*   **Analysis:** Revenue is relatively stable. Profit margins are high.  Equity has been declining, and ROE is consistently negative, indicating poor profitability relative to shareholder equity.

**7. Overall Analysis**

Teladoc Health (TDOC) is facing significant challenges.  It has severely underperformed the S&P 500, and its financial performance shows consistent losses (negative EPS and ROE). While revenue has been stable and profit margins are high, declining equity and large negative expected returns raise serious concerns. Recent news suggests potential catalysts are affecting the stock, leading to volatility. The recent price increase might be a short-term reaction to these catalysts, but the underlying financial issues remain.  The high profit margin and negative income suggest that there is high operating leverage in this business; a small revenue decline would create a very large impact on the profit.
